Taevas
TaiwanPharmaceuticals
Product Registration
Product Registration for Pharmaceuticals in Taiwan
Taevas Global guides pharmaceuticals manufacturers through every stage of TFDA product registration, from dossier preparation to approval, so you can enter Taiwan's dynamic market with confidence and speed.
Market
Taiwan
Industry
Pharmaceuticals
Service
Product Registration
Regulator
Taiwan Food and Drug Administration (TFDA)
Timeline
12-24 months typical NDA review
What We Deliver
Six Pillars of Taiwan Pharmaceuticals Intelligence
Our six interconnected pillars cover every dimension of TFDA product registration, giving pharmaceuticals companies a complete, actionable foundation for Taiwan market entry.
01
Regulatory Pathway Assessment
We map the precise TFDA registration pathway for your pharmaceutical product, whether it is a new drug application, generic drug, or biosimilar. Our team identifies the correct classification, required dossier components, and applicable TFDA guidelines before a single document is drafted. This upfront clarity prevents costly rework and timeline slippage.
NDA, ANDA, and biosimilar pathway mapping
Product classification under TFDA drug categories
Identification of applicable TFDA technical guidelines
How It Works
From Brief to Board-Ready Intelligence
Our four-stage engagement model takes you from initial scoping through to a fully approved TFDA registration strategy, with clear milestones and deliverables at every step.
Step 1 · Day 1-3
Scoping and Regulatory Gap Analysis
We begin with a structured intake session to understand your product profile, existing data package, target indication, and commercial timeline. Our regulatory specialists then conduct a formal gap analysis against current TFDA requirements to identify missing data, documentation deficiencies, and strategic risks. You receive a written gap report and recommended pathway within the first three days.
Taevas Approach
The gap analysis covers CTD module completeness, GMP site status, local agent requirements, and any bridging study obligations under TFDA ethnic sensitivity guidance. We also flag any parallel ICH or regional requirements that may affect your global dossier strategy, ensuring Taiwan registration is aligned with your broader market access plan.
Market Snapshot
Taiwan Pharmaceuticals Market at a Glance
$0B+
Taiwan Pharma Market Size (USD)
0%
Estimated Annual Market Growth
0+
Licensed Pharmaceutical Manufacturers
0+
New Drug Applications Filed Annually
TFDA as a Regional Regulatory Benchmark
Taiwan's TFDA has aligned its drug review processes closely with ICH guidelines and references approvals from stringent regulatory authorities including the US FDA, EMA, and Japan PMDA, enabling potential use of foreign clinical data. This convergence makes Taiwan an attractive and relatively efficient entry point for companies already holding approvals in major markets. TFDA's technical guidelines are regularly updated to reflect global best practices, reducing the regulatory distance for multinational applicants.
National Health Insurance Coverage Imperative
Taiwan operates one of the world's most comprehensive single-payer National Health Insurance systems, covering over 99 percent of the population, making NHI listing essential for commercial viability of most pharmaceutical products. Reimbursement decisions are made by the National Health Insurance Administration and are separate from TFDA registration, requiring a distinct strategy and timeline. Pricing negotiations under NHI can be complex, and early engagement with the reimbursement process is critical to a successful commercial launch.
Growing Demand for Innovative and Biologic Therapies
Taiwan's ageing population and high prevalence of chronic diseases including diabetes, cardiovascular disease, and cancer are driving sustained demand for innovative pharmaceuticals and biologics. The government has prioritized biotech and pharmaceutical innovation as a pillar of its industrial policy, with incentives for companies establishing R&D or manufacturing operations in Taiwan. This policy environment creates favorable conditions for innovative drug registrations and accelerated review pathways for products addressing unmet medical needs.
Generics Market and Local Manufacturing Strength
Taiwan has a well-developed domestic generics industry with over 400 licensed manufacturers, creating both a competitive landscape and a rich ecosystem of potential local partners for foreign entrants. TFDA's abbreviated new drug application process for generics is well-established, and bioequivalence study requirements are aligned with international standards. Foreign companies entering the generics segment often benefit from partnering with local manufacturers for cost-efficient production and established TFDA relationships.
What's Included
Everything in Your Report
Every Product Registration engagement for Taiwan Pharmaceuticals delivers a comprehensive set of documents and strategic assets designed to take you from application to approval.
Regulatory Pathway Report
A written assessment of the applicable TFDA registration pathway for your product, including classification, required modules, and estimated timeline with key milestones.
CTD Dossier Package
A complete Common Technical Document compiled and reviewed to TFDA standards, with Module 1 administrative documents localized in Traditional Chinese and English.
Regulatory Gap Analysis
A detailed gap analysis identifying missing data, documentation deficiencies, and strategic risks relative to current TFDA requirements, with prioritized remediation recommendations.
Risk and Strategy Memorandum
A strategic memorandum outlining regulatory risks, bridging study obligations, labeling strategy, and recommended mitigation actions tailored to your product and target indication.
Local Agent and GMP Site Report
A shortlist of vetted TFDA-licensed local agents and a GMP site compliance summary confirming readiness for TFDA manufacturing site registration.
TFDA Correspondence Log
A complete log of all TFDA interactions, deficiency queries, and responses maintained throughout the review process, providing a full regulatory history for your records.
Post-Approval Compliance Calendar
A forward-looking compliance calendar covering license renewal dates, pharmacovigilance reporting obligations, and any post-market surveillance commitments required by TFDA.
NHI Market Access Briefing
An executive briefing on Taiwan's NHI listing process, standard reimbursement pricing benchmarks, and recommended timeline for initiating reimbursement negotiations post-approval.
Who This Is For
Built for These Situations
Market Entry
Foreign Pharma Company Entering Taiwan for the First Time
You hold regulatory approvals in the US, EU, or Japan and are now evaluating Taiwan as your next Asian market. You need a clear understanding of TFDA requirements, local agent obligations, and the fastest viable pathway to registration without duplicating your existing global dossier. Taiwan's alignment with ICH standards offers real efficiency, but local nuances require expert navigation.
Outcome
A submission-ready TFDA dossier, appointed local agent, and a registration timeline that aligns with your Asia Pacific commercial rollout plan.
Next Steps
After Product Registration, Most Clients Move To
FAQ
Common Questions
Get Started
Ready to Map Your Taiwan Opportunity?
Whether you are filing your first TFDA application or optimizing an existing Taiwan regulatory strategy, Taevas Global has the in-country expertise and process discipline to get your pharmaceutical product registered and on the market.
End-to-end TFDA dossier preparation and submission management
In-country regulatory experts fluent in TFDA requirements and Traditional Chinese
Vetted local agent network and GMP site compliance support
Integrated post-approval market access and NHI listing guidance